New Techniques in MRI for detecting and Staging of Prostate Cancer | MRI
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
MRI New Techniques in MRI for detecting and Staging of Prostate Cancer

New Techniques in MRI for detecting and Staging of Prostate Cancer

Radiology News
MRI is the most promising technique available for adequate localization of prostate carcinoma.
For diagnosing prostate cancer, Transrectal Ultrasound (TRUS) guided prostate biopsy, initiated by elevated PSA-levels or a Digital Rectal Examination (DRE) suspicious for prostate cancer is the gold standard.  However TRUS and TRUS-guided biopsies are known to have high false-negative rates, up to 30% with random sextant biopsies 1, 2.  In the PSA era probably more low-volume prostate cancers are detected, leading to higher false-negative rates with random TRUS-guided biopsies, even when schemes with increasing numbers of random biopsy cores are used.

In the evaluation of prostate carcinoma anatomical T2-weighted MRI has been established to outperform DRE and TRUS in patients with an elevated PSA.  The spreading availability of 3 Tesla MR devices increases the performance of T2-weighted sequences.

Recent improvements in MR Techniques are MR Spectroscopy, Diffusion-Weighted MR Imaging (DWI) and Dynamic Contrast Enhanced (DCE) MRI.  These techniques improved the performance of MRI as a detection, localization and staging tool and able to characterize prostate cancer.    As the architectural combined Gleason score remains the foremost prognostic parameter in prostate cancer, the ability to predict Gleason score is of utmost importance. Hypothetically the characteristics imaged by DWI and DCE-MR, respectively cellular density and neo-angiogenesis, might correlate well with the Gleason score and consequently aggressiveness of the tumor 7. With an emerging spectrum of therapeutic options to be considered, ranging from active surveillance to radiotherapy and surgery, this information could be a cornerstone in clinical decision-making.

MRI is the choice for localization of prostate cancer in patients with the suspicion of its persistence, if the TRUS-guided prostate biopsy with serial negative.   MRI will enhance the accuracy of pre-treatment staging and grading of prostate cancer, aiding in decisions on treatment.


Source: UroToday.com.
 

Related Articles

Breaking News